News

Experimental CFTR modulators show promise in preclinical tests

Two experimental CFTR modulator therapies being developed by Sionna Therapeutics are able to improve the function of the most common mutated form of CFTR protein that causes cystic fibrosis (CF). That’s according to new data Sionna presented at the European Cystic Fibrosis Society (ECFS) 48th European Cystic Fibrosis…

NBD1 stabilizers safe in healthy volunteers, Sionna says

SION-719 and SION-451, two NBD1 stabilizers Sionna Therapeutics is developing to restore CFTR protein function in cystic fibrosis (CF), will advance to the next stages of clinical development after positive safety results in Phase 1 clinical trials. Sionna tested both compounds in healthy volunteers to assess safety and…

Inhaled antibiotics linked to increased risk of fungal infections

Using inhaled antibiotics can help control the growth of certain bacteria in the lungs, but it may increase the risk of fungal infections with Aspergillus fumigatus in people with cystic fibrosis (CF), according to a study. The study, “Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis,”…

Signaling molecule PI5P shows promise for treating CF infections

Scientists have discovered a potential therapy for cystic fibrosis (CF) patients who are infected with Mycobacterium abscessus, a bacterium that can cause serious lung infections. They found that a signaling molecule called PI5P can boost the antimicrobial activity of immune cells isolated from patients against the bacterium. This happens even…